Postoperative iliac fascia nerve block analgesia in patients undergoing hip arthroplasty
Conditions
Interventions
control group:0.33% Ropivacaine 30mL
Experimental group:0.33% Ropivacaine 30mL+10mg Oxycodone Hydrochloride
Sponsors
The Central Hospital of Enshi Tujia and Miao Autonomous Prefesture
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-65 years; 2. Patients undergoing elective hip arthroplasty; 3. ASA grade I-II; 4. No serious cardiovascular or cerebrovascular disease, normal liver or kidney function, and no other special medical history of anesthetic drug allergy. Patients with any of the following exclusion criteria cannot be enrolled in this study; 5. Patients or their families have full understanding of the purpose and significance of this trial, voluntarily participate in this clinical trial, and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients whose physical condition is difficult to evaluate for efficacy (e.g., severe central nervous system surgery or intracranial surgery); 2. Patients with diabetes mellitus whose blood glucose is not satisfactorily controlled (fasting glucose 11.1 mmol/L during the screening period); 3. History of myocardial infarction, unstable angina within 6 months prior to the screening period; 4. Patients with bradycardia (heart rate 1.5 times the upper limit of normal, APTT > 1.5 times the upper limit of normal), with bleeding tendency (e.g., active peptic ulcer) or undergoing thrombolytic or anticoagulant therapy; 8. Abnormal liver function with ALT and/or AST > 1.5 times the upper limit of normal; 9. Abnormal renal function with blood creatinine (Cr) and/or urea nitrogen (BUN) > 1.5 times the upper limit of normal values; dialysis patients; 10. Hypersensitivity to the components or constituents of the test drug; 11. Women who are pregnant or breastfeeding; 12. Participation in clinical trials of other drugs within 3 months; 13. Patients with myasthenia gravis, schizophrenia, major depressive states; 14. Patients who are allergic to opioids.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to patient's first postoperative remedial analgesia (T1); | — |
Secondary
| Measure | Time frame |
|---|---|
| Sensory block onset time (T2);Motor block onset time (T3);Maintenance time of sensory block (T4);Maintenance time of motor block (T5); | — |
Countries
China
Contacts
Public ContactZhu Xianlin
The Central Hospital of Enshi Tujia and Miao Autonomous Prefesture
Outcome results
None listed